These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

255 related items for PubMed ID: 12103271

  • 1. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers synergistically increase coronary blood flow in canine ischemic myocardium: role of bradykinin.
    Kitakaze M, Asanuma H, Funaya H, Node K, Takashima S, Sanada S, Asakura M, Ogita H, Kim J, Hori M.
    J Am Coll Cardiol; 2002 Jul 03; 40(1):162-6. PubMed ID: 12103271
    [Abstract] [Full Text] [Related]

  • 2. Beneficial effects of inhibition of angiotensin-converting enzyme on ischemic myocardium during coronary hypoperfusion in dogs.
    Kitakaze M, Minamino T, Node K, Komamura K, Shinozaki Y, Mori H, Kosaka H, Inoue M, Hori M, Kamada T.
    Circulation; 1995 Aug 15; 92(4):950-61. PubMed ID: 7641379
    [Abstract] [Full Text] [Related]

  • 3. Inhibition of angiotensin-converting enzyme increases the nitric oxide levels in canine ischemic myocardium.
    Kitakaze M, Node K, Minamino T, Asanuma H, Ueda Y, Kosaka H, Kuzuya T, Hori M.
    J Mol Cell Cardiol; 1998 Nov 15; 30(11):2461-6. PubMed ID: 9925380
    [Abstract] [Full Text] [Related]

  • 4. Chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade: effects on cardiovascular remodeling in rats induced by the long-term blockade of nitric oxide synthesis.
    Takemoto M, Egashira K, Tomita H, Usui M, Okamoto H, Kitabatake A, Shimokawa H, Sueishi K, Takeshita A.
    Hypertension; 1997 Dec 15; 30(6):1621-7. PubMed ID: 9403592
    [Abstract] [Full Text] [Related]

  • 5. Cardioprotection with angiotensin converting enzyme inhibitor and angiotensin II type 1 receptor antagonist is not abolished by nitric oxide synthase inhibitor in ischemia-reperfused rabbit hearts.
    Kawabata H, Ryomoto T, Ishikawa K.
    Hypertens Res; 2001 Jul 15; 24(4):403-9. PubMed ID: 11510753
    [Abstract] [Full Text] [Related]

  • 6. The role of bradykinin and nitric oxide in the cardioprotective action of ACE inhibitors.
    Hartman JC.
    Ann Thorac Surg; 1995 Sep 15; 60(3):789-92. PubMed ID: 7545893
    [Abstract] [Full Text] [Related]

  • 7. Effect of selective angiotensin II receptor antagonism and angiotensin converting enzyme inhibition on the coronary vasculature in vivo. Intravascular two-dimensional and Doppler ultrasound studies.
    Sudhir K, MacGregor JS, Gupta M, Barbant SD, Redberg R, Yock PG, Chatterjee K.
    Circulation; 1993 Mar 15; 87(3):931-8. PubMed ID: 8383016
    [Abstract] [Full Text] [Related]

  • 8. Synergy of amlodipine and angiotensin-converting enzyme inhibitors in regulating myocardial oxygen consumption in normal canine and failing human hearts.
    Mital S, Loke KE, Slater JP, Addonizio L, Gersony WM, Hintze TH.
    Am J Cardiol; 1999 Jun 17; 83(12A):92H-98H. PubMed ID: 10750596
    [Abstract] [Full Text] [Related]

  • 9. Endothelium dependent vasomotor responses to endogenous agonists are potentiated following ACE inhibition by a bradykinin dependent mechanism.
    Zanzinger J, Zheng X, Bassenge E.
    Cardiovasc Res; 1994 Feb 17; 28(2):209-14. PubMed ID: 8143302
    [Abstract] [Full Text] [Related]

  • 10. Angiotensin-converting enzyme inhibitors improve coronary flow reserve in dilated cardiomyopathy by a bradykinin-mediated, nitric oxide-dependent mechanism.
    Nikolaidis LA, Doverspike A, Huerbin R, Hentosz T, Shannon RP.
    Circulation; 2002 Jun 11; 105(23):2785-90. PubMed ID: 12057995
    [Abstract] [Full Text] [Related]

  • 11. Carperitide induces coronary vasodilation and limits infarct size in canine ischemic hearts: role of NO.
    Asanuma H, Sanada S, Asakura M, Asano Y, Kim J, Shinozaki Y, Mori H, Minamino T, Takashima S, Kitakaze M.
    Hypertens Res; 2014 Aug 11; 37(8):716-23. PubMed ID: 24694647
    [Abstract] [Full Text] [Related]

  • 12. Nifedipine-induced coronary vasodilation in ischemic hearts is attributable to bradykinin- and NO-dependent mechanisms in dogs.
    Kitakaze M, Asanuma H, Takashima S, Minamino T, Ueda Y, Sakata Y, Asakura M, Sanada S, Kuzuya T, Hori M.
    Circulation; 2000 Jan 25; 101(3):311-7. PubMed ID: 10645928
    [Abstract] [Full Text] [Related]

  • 13. Coronary vasodilation induced by angiotensin-converting enzyme inhibition in vivo: differential contribution of nitric oxide and bradykinin in conductance and resistance arteries.
    Sudhir K, Chou TM, Hutchison SJ, Chatterjee K.
    Circulation; 1996 May 01; 93(9):1734-9. PubMed ID: 8653880
    [Abstract] [Full Text] [Related]

  • 14. Bradykinin stimulates the release of tissue plasminogen activator in human coronary circulation: effects of angiotensin-converting enzyme inhibitors.
    Minai K, Matsumoto T, Horie H, Ohira N, Takashima H, Yokohama H, Kinoshita M.
    J Am Coll Cardiol; 2001 May 01; 37(6):1565-70. PubMed ID: 11345366
    [Abstract] [Full Text] [Related]

  • 15. Angiotensin-(1-7) augments bradykinin-induced vasodilation by competing with ACE and releasing nitric oxide.
    Li P, Chappell MC, Ferrario CM, Brosnihan KB.
    Hypertension; 1997 Jan 01; 29(1 Pt 2):394-400. PubMed ID: 9039133
    [Abstract] [Full Text] [Related]

  • 16. Vasopeptidase inhibitor omapatrilat induces profound insulin sensitization and increases myocardial glucose uptake in Zucker fatty rats: Studies comparing a vasopeptidase inhibitor, angiotensin-converting enzyme inhibitor, and angiotensin II type I receptor blocker.
    Wang CH, Leung N, Lapointe N, Szeto L, Uffelman KD, Giacca A, Rouleau JL, Lewis GF.
    Circulation; 2003 Apr 15; 107(14):1923-9. PubMed ID: 12668518
    [Abstract] [Full Text] [Related]

  • 17. Bradykinin mediation of Ca(2+)-activated K+ channels regulates coronary blood flow in ischemic myocardium.
    Node K, Kitakaze M, Kosaka H, Minamino T, Hori M.
    Circulation; 1997 Mar 18; 95(6):1560-7. PubMed ID: 9118526
    [Abstract] [Full Text] [Related]

  • 18. A calcium channel blocker amlodipine increases coronary blood flow via both adenosine- and NO-dependent mechanisms in ischemic hearts.
    Asanuma H, Minamino T, Sanada S, Ogita H, Kim J, Fujita M, Hirata A, Tsukamoto O, Ogai A, Node K, Hori M, Tomoike H, Kitakaze M.
    J Mol Cell Cardiol; 2005 Oct 18; 39(4):605-14. PubMed ID: 16087189
    [Abstract] [Full Text] [Related]

  • 19. Local inhibition of bradykinin degradation in ischemic hearts.
    Linz W, Martorana PA, Schölkens BA.
    J Cardiovasc Pharmacol; 1990 Oct 18; 15 Suppl 6():S99-109. PubMed ID: 1697370
    [Abstract] [Full Text] [Related]

  • 20. In vivo inhibition of nitric oxide synthesis does not depend on renin-angiotensin system activation.
    Zappellini A, Teixeira SA, Muscará MN, Zatz R, Antunes E, De Nucci G.
    Eur J Pharmacol; 1996 Dec 19; 317(2-3):285-91. PubMed ID: 8997612
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.